Lyna Tablet contains a combination of Ethinyl Estradiol (0.03 mg) and Levonorgestrel (0.15 mg), which are synthetic hormones used primarily for oral contraception. Ethinyl Estradiol is a synthetic estrogen, while Levonorgestrel is a synthetic progestin; together, they work synergistically to prevent ovulation, alter the cervical mucus to inhibit sperm penetration, and modify the endometrial lining to prevent implantation. Lyna Tablet is indicated for the prevention of pregnancy in women of reproductive age seeking effective birth control. It is administered orally, typically once daily, following the prescribed regimen to ensure optimal efficacy. The combination has been extensively studied and is known for its high contraceptive reliability when taken correctly. Patients should be advised of potential side effects, including nausea, breast tenderness, headache, and breakthrough bleeding, which are generally mild and transient. Contraindications include a history of thromboembolic disorders, hormone-sensitive malignancies, liver disease, and known hypersensitivity to any component of the tablet. Prior to initiation, a thorough medical history and risk assessment are essential to minimize adverse effects. Lyna Tablet does not protect against sexually transmitted infections. Regular follow-up is recommended to monitor tolerance and adherence.